Abstract |
To evaluate the potential role of serotonin in the premenstrual syndrome (PMS), we investigated the effects of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonergic agent m-chlorophenylpiperazine ( m-CPP) in women with PMS and controls. A single oral dose of m-CPP (0.5 mg/kg) was administered to 10 PMS patients and 10 healthy controls during the follicular and luteal phases of the menstrual cycle. We observed the following. m-CPP administration during the luteal phase resulted in an acute improvement of PMS symptoms; the plasma cortisol and ACTH responses to m-CPP were blunted in both menstrual cycle phases in PMS patients compared with controls. These data provide evidence for the acute efficacy of m-CPP in the treatment of PMS. Although there is additional evidence for dysregulation of either the hypothalamic-pituitary-adrenal axis or serotonin control of the hypothalamic-pituitary-adrenal axis in women with PMS, there is little evidence for luteal phase-specific serotonergic dysfunction. These findings, nonetheless, implicate the serotonin system as a modulating (not causal) factor in PMS.
|
Authors | T P Su, P J Schmidt, M Danaceau, D L Murphy, D R Rubinow |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 82
Issue 4
Pg. 1220-8
(Apr 1997)
ISSN: 0021-972X [Print] United States |
PMID | 9100599
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Hormones
- Piperazines
- Serotonin Receptor Agonists
- 1-(3-chlorophenyl)piperazine
|
Topics |
- Adult
- Affect
(drug effects)
- Behavior
(drug effects)
- Female
- Follicular Phase
- Hormones
(blood)
- Humans
- Luteal Phase
- Menstrual Cycle
- Neurosecretory Systems
(drug effects)
- Piperazines
(blood, therapeutic use)
- Premenstrual Syndrome
(drug therapy, physiopathology, psychology)
- Reference Values
- Self Concept
- Serotonin Receptor Agonists
(pharmacology)
|